Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Prevention of AKI Post-PCI
NCT05435235Phase 4Suspended
- Sponsor
- Einstein Healthcare Network
- Start
- Sep 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in acute kidney injury (AKI), sponsored by Einstein Healthcare Network. Started Sep 2024; status: suspended.
02
Drugs
dapagliflozin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05435235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435235.